Related Experiment Video

Updated: Jun 23, 2026

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

New treatments for malignant gliomas: careful evaluation and cautious optimism required

Mark R Gilbert

    Annals of Internal Medicine
    |March 8, 2006
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
    09:33

    Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

    Published on: March 20, 2026

    Related Experiment Videos

    Last Updated: Jun 23, 2026

    Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
    08:02

    Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

    Published on: March 6, 2012

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
    09:33

    Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

    Published on: March 20, 2026

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Evaluating Dysphonia Referrals to Otolaryngology Providers: Is There a Need For Improved Referral Guideline Implementation?

    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026

    Phase I trial and pharmacokinetic study of berubicin (RTA 744) in patients with recurrent or refractory high-grade gliomas.

    Neuro-oncology advances·2026

    Natural history study of adults with primary central nervous system tumors: Initial results for first 1000 participants.

    Neuro-oncology practice·2026

    Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

    medRxiv : the preprint server for health sciences·2026

    Inhibition of chemokine CXCL12 modulates the tumor microenvironment in glioblastoma and potentiates immune checkpoint inhibitor efficacy in a tissue-specific manner.

    Neuro-oncology advances·2026

    Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Periconception Parental Red Blood Cell Folate, Vitamin B12, and Birth Defects in Offspring : A Prospective Cohort Study.

    Annals of internal medicine·2026

    In adults with CKM syndrome, finerenone vs. placebo reduced sudden death at a median 2.9 y.

    Annals of internal medicine·2026

    In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo.

    Annals of internal medicine·2026

    A single colonoscopy screening invitation vs. no invitation reduced colorectal cancer incidence but not related mortality at 13 y.

    Annals of internal medicine·2026

    In adults with early uncontrolled T2D, tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y.

    Annals of internal medicine·2026

    Ethics and Professionalism in Artificial Intelligence and Medical Practice: A Position Paper From the American College of Physicians.

    Annals of internal medicine·2026

    TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.

    The Journal of experimental medicine·2026

    Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC.

    Molecular cancer therapeutics·2026

    Toward Fit-for-Purpose Data for Drug Assessment in Non-small Cell Lung Cancer: A Core Dataset.

    Clinical pharmacology and therapeutics·2026

    Regulation of the lncRNA NEAT1 by p53-ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC.

    Molecular oncology·2026

    Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer.

    Molecular pharmaceutics·2026

    Preclinical Evaluation of [68Ga]Ga-CS03 as a Novel GPC3-Targeted Probe for Imaging GPC3 in Hepatocellular Carcinoma Models.

    Molecular pharmaceutics·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us